Abouljoud M S, Deierhoi M H, Hudson S L, Diethelm A G
Department of Surgery, University of Alabama at Birmingham 35294, USA.
Transplantation. 1995 Jul 27;60(2):138-44.
Removal of a failed primary renal allograft was found by some groups to adversely affect the outcome of a second kidney transplant. Recent data does not support this view and fail to show any such effect. Such data, however, are limited by small numbers or univariate analysis. The records of 192 patients receiving a primary and a subsequent kidney transplant between January 1980 and July 1992 were retrospectively reviewed. Immunosuppression initially included azathioprine and prednisone; cyclosporine was introduced in December 1983 with Minnesota antilymphocyte globulin (MALG) added for induction in May 1987. Regraft survival rates were 66% at one year and 60% at two years. Using Kaplan-Meier survival analysis patients having primary transplant nephrectomy had a worse second allograft outcome than patients who kept their failed grafts (P = 0.0003). Multivariate analysis showed a significant relationship between primary allograft survival and retransplant outcome. To eliminate this influence, patients whose first graft failed within six months of transplantation were excluded from the analysis. This resulted in 90 patients whose first graft functioned for more than 6 months. Graft survival was 80% at one year and 73% at 2 years in this select population. Patients with prior transplant nephrectomy still had a worse retransplant outcome than those who kept their failed grafts (P = 0.05). Multivariate analysis identified primary allograft nephrectomy, older donor age, longer interval from nephrectomy to retransplant, and lack of MALG at induction as negative risk factors. In conclusion, primary allograft nephrectomy may have a negative influence on second renal transplant outcome. This result may be improved by reducing donor age and the time interval from nephrectomy to retransplantation, and using MALG at induction.
一些研究小组发现,切除失败的初次肾移植同种异体移植物会对第二次肾移植的结果产生不利影响。近期数据并不支持这一观点,也未显示出任何此类影响。然而,此类数据因样本量小或单变量分析而受到限制。对1980年1月至1992年7月期间接受初次及后续肾移植的192例患者的记录进行了回顾性分析。免疫抑制最初包括硫唑嘌呤和泼尼松;1983年12月引入环孢素,并于1987年5月添加明尼苏达抗淋巴细胞球蛋白(MALG)用于诱导。再次移植的1年生存率为66%,2年生存率为60%。使用Kaplan-Meier生存分析,接受初次移植肾切除术的患者第二次同种异体移植的结果比保留失败移植物的患者更差(P = 0.0003)。多变量分析显示初次同种异体移植的存活与再次移植的结果之间存在显著关系。为消除这种影响,将移植后6个月内首次移植物失败的患者排除在分析之外。这产生了90例首次移植物功能超过6个月的患者。在这个特定人群中,移植物1年生存率为80%,2年生存率为73%。先前接受过移植肾切除术的患者再次移植的结果仍然比保留失败移植物的患者更差(P = 0.05)。多变量分析确定初次同种异体移植肾切除术、供体年龄较大、从肾切除到再次移植的间隔时间较长以及诱导时未使用MALG为负面风险因素。总之,初次同种异体移植肾切除术可能会对第二次肾移植的结果产生负面影响。通过降低供体年龄、缩短从肾切除到再次移植的时间间隔以及在诱导时使用MALG,这一结果可能会得到改善。